Inovio Pharmaceuticals, Inc. (INO)

3.80
0.06 1.55
NASDAQ
Prev Close 3.86
Open 3.88
Day Low/High 3.75 / 3.88
52 Wk Low/High 3.63 / 6.30
Volume 1.01M
Exchange NASDAQ
Shares Outstanding 97.93B
Market Cap 372.15M
Div & Yield N.A. (N.A)

Latest News

Inovio's Phase 3 HPV Immunotherapy Selected As "Best Therapeutic Vaccine" At World Vaccine Congress

Inovio's Phase 3 HPV Immunotherapy Selected As "Best Therapeutic Vaccine" At World Vaccine Congress

PLYMOUTH MEETING, Pa., April 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Aerie and Inovio Among Pharma Stocks Offering High Risk and Even Higher Upside

Aerie and Inovio Among Pharma Stocks Offering High Risk and Even Higher Upside

Risk and reward are the yin and yang of investing, and are closely related, especially in the pharmaceutical field.

Inovio Achieves Third Cancer Indication Milestone For MEDI0457 Phase 2 Development

Inovio Achieves Third Cancer Indication Milestone For MEDI0457 Phase 2 Development

PLYMOUTH MEETING, Pa., April 8, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors In Pilot Clinical Study

Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors In Pilot Clinical Study

Clinical Data Presented at Annual Meeting of American Association for Cancer Research

Inovio Presents Cancer Killing Data Of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) At AACR

Inovio Presents Cancer Killing Data Of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) At AACR

Data demonstrates tumor-clearing ability of Inovio's dBiTE technology in preclinical cancer model

Inovio Completes Enrollment Ahead Of Schedule In Immuno-Oncology Study For Glioblastoma (GBM) With INO-5401 In Combination With Regeneron's PD-1 Inhibitor

Inovio Completes Enrollment Ahead Of Schedule In Immuno-Oncology Study For Glioblastoma (GBM) With INO-5401 In Combination With Regeneron's PD-1 Inhibitor

PLYMOUTH MEETING, Pa., April 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals To Present At H.C. Wainwright Global Life Sciences Conference In London, UK

Inovio Pharmaceuticals To Present At H.C. Wainwright Global Life Sciences Conference In London, UK

PLYMOUTH MEETING, Pa., March 27, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio Appoints Global Commercial Leader To Its Board Of Directors

Inovio Appoints Global Commercial Leader To Its Board Of Directors

PLYMOUTH MEETING, Pa., March 25, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

First Week Of INO November 15th Options Trading

First Week Of INO November 15th Options Trading

Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the November 15th expiration.

Inovio Pharmaceuticals Reports 2018 Fourth Quarter And Year-End Financial Results

Inovio Pharmaceuticals Reports 2018 Fourth Quarter And Year-End Financial Results

PLYMOUTH MEETING, Pa., March 12, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio Appoints Chief Operating Officer; Announces Strategic Management Changes

Inovio Appoints Chief Operating Officer; Announces Strategic Management Changes

PLYMOUTH MEETING, Pa., March 12, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals To Announce Fourth Quarter And Full Year 2018 Financial Results And Host Conference Call On March 12, 2019

Inovio Pharmaceuticals To Announce Fourth Quarter And Full Year 2018 Financial Results And Host Conference Call On March 12, 2019

PLYMOUTH MEETING, Pa., March 5, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio Initiates REVEAL 2 Global Phase 3 Clinical Study For The Treatment Of HPV-Related Cervical Pre-cancer

Inovio Initiates REVEAL 2 Global Phase 3 Clinical Study For The Treatment Of HPV-Related Cervical Pre-cancer

The second Phase 3 study initiation announcement made during the International HPV Awareness Day

Inovio Pharmaceuticals Completes Sale Of Additional Convertible Senior Notes

Inovio Pharmaceuticals Completes Sale Of Additional Convertible Senior Notes

PLYMOUTH MEETING, Pa., March 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Geneos Therapeutics Secures $10.5 Million In Series A Financing To Develop The Next Generation Of Neoantigen-Targeting Cancer Immunotherapies

Geneos Therapeutics Secures $10.5 Million In Series A Financing To Develop The Next Generation Of Neoantigen-Targeting Cancer Immunotherapies

Geneos has Licensed Immunotherapy Platform from Inovio Pharmaceuticals for Developing Personalized Cancer Treatments

Inovio Pharmaceuticals Prices $65.0 Million Convertible Senior Notes Offering

Inovio Pharmaceuticals Prices $65.0 Million Convertible Senior Notes Offering

PLYMOUTH MEETING, Pa., Feb.

Inovio Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

Inovio Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

PLYMOUTH MEETING, Pa., Feb.

INO Crosses Below Key Moving Average Level

INO Crosses Below Key Moving Average Level

In trading on Tuesday, shares of Inovio Pharmaceuticals Inc. crossed below their 200 day moving average of $4.77, changing hands as low as $4.72 per share.

Inovio's DMAb™ PD-1 Checkpoint Inhibitors Demonstrate Higher And More Prolonged Expression Compared To Native Pembrolizumab And Nivolumab Sequences In Preclinical Studies

Inovio's DMAb™ PD-1 Checkpoint Inhibitors Demonstrate Higher And More Prolonged Expression Compared To Native Pembrolizumab And Nivolumab Sequences In Preclinical Studies

PD-1 DNA-encoded monoclonal antibodies (dMAbs) highlighted in a paper published in cancer journal Oncotarget

Inovio Pharmaceuticals (INO) Shares Cross Above 200 DMA

Inovio Pharmaceuticals (INO) Shares Cross Above 200 DMA

In trading on Monday, shares of Inovio Pharmaceuticals Inc. crossed above their 200 day moving average of $4.76, changing hands as high as $4.96 per share.

Inovio's DNA-Encoded Monoclonal Antibody (dMAb™) Platform Leaps Forward With First-in-Human Trial

Inovio's DNA-Encoded Monoclonal Antibody (dMAb™) Platform Leaps Forward With First-in-Human Trial

First Human dMAb Study Will Target Zika Infection

Interesting INO Put And Call Options For August 16th

Interesting INO Put And Call Options For August 16th

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the August 16th expiration.

Inovio Announces Appointments To Its Board Of Directors

Inovio Announces Appointments To Its Board Of Directors

Simon X. Benito, Director Since 2003, Named Chairman of the Board; Lota Zoth, former MedImmune CFO, Joins Board

Interesting INO Put And Call Options For October 19th

Interesting INO Put And Call Options For October 19th

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the October 19th expiration.

Bullish Two Hundred Day Moving Average Cross - INO

Bullish Two Hundred Day Moving Average Cross - INO

In trading on Tuesday, shares of Inovio Pharmaceuticals Inc. crossed above their 200 day moving average of $4.51, changing hands as high as $4.54 per share.

Interesting INO Put And Call Options For February 2019

Interesting INO Put And Call Options For February 2019

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the February 2019 expiration.

TheStreet Quant Rating: D (Sell)